American businesses feel increasingly less welcome in China, according to a new survey, with rising protectionism in the mainland a top concern.» Read More
Federal Reserve Chairman Ben Bernanke said the economy should grow at a slow pace before recovering later in the year. What's the word on the Street?
The markets had a Warren Buffett rally on Tuesday, but tomorrow's news could just as easily send stocks plummeting again.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
GlaxoSmithKline forecast lower 2008 earnings due to falling sales of diabetes drug Avandia and increased generic competition, sending shares in Europe's biggest drugmaker down 7.6 percent on Thursday.
Shares of GlaxoSmithKline this morning are getting hammered because the company announced it expects earnings per share to fall by a mid-single digit percentage this year. Analysts thought they'd grow by three percent.
Cisco's downbeat earnings comments could make a dent in stocks Thursday morning. Ahead of the opening bell, investors will also be watching rate meetings by the European Central Bank and the Bank of England.
Reaction to part of a big government-sponsored diabetes drug study being halted over fatalities is pouring in from several corners. The American Diabetes Association put out a press release saying it "strongly encourages people with diabetes not to alter their course of treatment without first consulting with their health care team...
Yes, it was a big down day for equities, but I wanted to call attention to the fact that according to one of our resident stock gurus, Robert Hum, the Amex Pharmaceutical Index (you can see the 15 stocks that make up the so-called DRG here) closed at a two-year low today.
Standard and Poor's has just released the results of its twice-a-year stock screen, designed to find Warren Buffett-style stocks. The new list features several tech stocks, including Apple, as well as a number of names from Europe and Asia. But some key Buffett criteria aren't taken into account by the screen.
At 1 pm ET today the embargo was supposed to lift on an article in the scientific journal "Nature" that we got advanced word on early this morning. We were set to post the write-through about it at that time on our web site.
The scientific journal Nature reported today that a peer-reviewer for The New England Journal of Medicine leaked key study results on GlaxoSmithKline's diabetes drug Avandia to the company weeks before they were published.
For the second time this week, big pharma is taking a beating from critical reports about medications. This time, it's antidepressants. But one analyst thinks the drag on shares is overdone -- and names "exciting" pharma stocks.
Swiss drug maker Novartis said Thursday its fourth-quarter profit fell sharply, mainly due to restructuring costs, but that it would increase returns to shareholders with a new buyback program and an increase to its dividend.
If or when you watch one of the presidential debates count how many times the candidates say, "the drug companies." Of course, it depends on which party's debate you might be watching, but since I started paying attention to the race in recent weeks, I've taken notice how much those three words seem to be apart of boilerplate answers and statements...
The European Commission raided some of the world's largest drugmakers on Wednesday, launching a broad investigation into whether they made illegal deals or abused patents to limit competition and harm consumers.
The highly anticipated results of the study that goes by the acronym "ENHANCE" are out this morning. You can see what it stands for in the companies' press release. (I wonder how many meetings and brainstorming sessions go into coming up with some of the industry's clinical trial acronyms and abbreviations.)
Kevin O'Marah, chief strategist at AMR Research, has developed a unique "supply-chain strategy" -- and uses it to compile a Top 25 stocks list that beat the 2007 market hands-down.
Eli Lilly Tuesday said U.S. regulators approved once-daily use of two low-dose forms of its Cialis anti-impotence drug, offering greater convenience for men expecting frequent sexual activity.
The seven biggest stories in my sectors in 2007? Avandia, Dendreon, Pfizer, Biogen were just a few of the topics that made this a fascinating year for the pharmaceuticals and biotechnology industries.
A Merrill Lynch research note to clients titled, "Diabetics scared off therapy," contains some interesting observations about what's happened to the oral diabetes drug market in the wake of the Avandia safety scare earlier this year.